ALA — Arovella Therapeutics Balance Sheet
0.000.00%
- AU$109.35m
- AU$88.47m
- AU$0.53m
Annual balance sheet for Arovella Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 6.72 | 6.07 | 5.18 | 12.7 | 20.9 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.534 | 0.036 | 0.01 | 0.175 | 0.113 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 7.34 | 6.59 | 5.42 | 13.2 | 21.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.433 | 0.371 | 0.05 | 0.131 | 0.431 |
| Net Intangible Assets | |||||
| Total Assets | 10.7 | 9.21 | 5.47 | 13.3 | 21.6 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.69 | 1.51 | 1.68 | 2.04 | 1.49 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.71 | 1.6 | 1.69 | 2.06 | 1.52 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 8.98 | 7.62 | 3.78 | 11.2 | 20.1 |
| Total Liabilities & Shareholders' Equity | 10.7 | 9.21 | 5.47 | 13.3 | 21.6 |
| Total Common Shares Outstanding |